Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

"All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W"